2-异丙烯基嘧啶 | 64958-59-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-异丙烯基嘧啶
• 英文名称: 2-isopropenyl-pyrimidine
• 英文别名: 2-Prop-1-en-2-ylpyrimidine
• CAS: 64958-59-4
• 化学式: C₇H₈N₂
• 分子量: 120.154
• InChiKey: UQYJXXBWOHRVBQ-UHFFFAOYSA-N

物化性质

• 沸点：
  92.4±13.0 °C(Predicted)
• 密度：
  0.987±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] ADENOSINE A2A RECEPTOR ANTAGONISTS AND USES THEREOF<br/>[FR] ANTAGONISTES DU RÉCEPTEUR A2A DE L'ADÉNOSINE ET LEURS UTILISATIONS
  申请人：TEON THERAPEUTICS INC

  公开号：WO2021011670A1

  公开（公告）日：2021-01-21

  Disclosed herein are compounds, compositions, and methods for modulating the A2A adenosine receptor with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the A2A adenosine receptor, such as cancer, with A2A adenosine receptor antagonists.

  本文披露了用于调节A2A腺苷受体的化合物、组合物和方法。还描述了利用A2A腺苷受体拮抗剂治疗由A2A腺苷受体介导的疾病或障碍的方法，如癌症。
• [EN] 8-SUBSTITUTED QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS<br/>[FR] QUINOLÉINES SUBSTITUÉES EN 8 ET ANALOGUES ASSOCIÉS UTILISÉS COMME MODULATEURS DE SIRTUINE
  申请人：SIRTRIS PHARMACEUTICALS INC

  公开号：WO2010101949A1

  公开（公告）日：2010-09-10

  Provided herein are 8-substituted quinolines and related analogues as sirtuin-modulating compounds of Structural Formula (I) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了8-取代喹啉和相关类似物作为结构式（I）的抑制素调节化合物以及其使用方法。这些抑制素调节化合物可用于延长细胞寿命，并用于治疗和/或预防各种疾病和紊乱，包括与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱，以及那些会受益于增加线粒体活性的疾病或紊乱。还提供了包含抑制素调节化合物与另一治疗剂结合的组合物。
• Process for the preparation of pyrimidine and 2-alkylpyrimidine
  申请人：STAMICARBON B.V.

  公开号：EP0192299A1

  公开（公告）日：1986-08-27

  The invention provides a process for the preparation of pyrimidine, 2-methyl- and/or 2-ethylpyrimidine, characterized in that for pyrimidine a nitrogen reactant, chosen from the reaction product of formamide with 1,3-diaminopropane in the liquid phase, 1-amino-3-formamidopropane, 1,4,5,6-tetrahydropyrimidine and/or 1,3-diformamidopropane, that for 2-methyipyrimidine 1-amino-3-acetamidopropane. 2-methyl-1,4,5,6- tetrahydropyrimidine and/or 1,3-diacetamidopropane, and that for 2-ethylpyrimidine 1-amino-3-propionamidopropane, 2-ethyl-1,4,5,6-tetrahydropyrimidine and/or 1,3- dipropionamidopropane is/are contacted with a palladium-containing catalyst, this being effected in the gas phase at a temperature between 200 and 550 □C and in the presence of a carbon monoxide-hydrogen reactant, and that pyrimidine, 2-methyl-and/or 2-ethyl-pyrimidine is recovered from the reaction mixture obtained.

  本发明提供了一种制备嘧啶、2-甲基和/或 2-乙基嘧啶的工艺，其特征在于，对于嘧啶，氮反应物选自甲酰胺与 1，3-二氨基丙烷在液相中的反应产物、 1-氨基-3-甲酰胺基丙烷、1,4,5,6-四氢嘧啶和/或 1,3-二甲酰胺基丙烷，2-甲基嘧啶的反应物为 1-氨基-3-乙酰胺基丙烷。2-甲基-1,4,5,6-四氢嘧啶和/或 1,3-二乙酰氨基丙烷，以及 2-乙基-1,4,5,6-四氢嘧啶和/或 1,3-二丙酰氨基丙烷，都要与含钯催化剂接触、在气相中，温度介于 200 ℃ 和 550 ℃ 之间，并有一氧化碳-氢反应物存在的情况下进行，从得到的反应混合物中回收嘧啶、2-甲基和/或 2-乙基嘧啶。
• US4775755A
  申请人：——

  公开号：US4775755A

  公开（公告）日：1988-10-04
• [EN] POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS<br/>[FR] DERIVES POLYCYCLIQUES D'INDAZOLE INHIBITEURS DES ERK
  申请人：SCHERING CORP

  公开号：WO2007070398A1

  公开（公告）日：2007-06-21

  [EN] Disclosed are the ERK inhibitors of formula 1.0 and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
  [FR] La présente invention concerne des inhibiteurs des kinases régulées par des signaux extracellulaires (ERK) de formule 1.0 et leurs sels et solvates pharmaceutiquement acceptables. Q est un cycle pipéridine ou pipérazine qui peut comporter un cycle fusionné ou un pont. Le cycle pipéridine peut comporter une double liaison. Tous les autres substituants sont tels que définis ici. L'invention concerne également des procédés de traitement du cancer à l'aide des composés de formule 1.0.